CytomX Therapeutics, Inc. Lessee, Operating Lease, Liability, to be Paid
CytomX Therapeutics, Inc. (CTMX) had Lessee, Operating Lease, Liability, to be Paid of $10.12 million as of 2024-12-31, per its 10-K filed 2025-03-06.
Financial Statements › Notes › Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue · last filed 2025-03-06
- 2024-12-31: Lessee, Operating Lease, Liability, to be Paid $10.12M.
- 2023-12-31: Lessee, Operating Lease, Liability, to be Paid $15.69M.
- 2022-12-31: Lessee, Operating Lease, Liability, to be Paid $21.11M.
- 2021-12-31: Lessee, Operating Lease, Liability, to be Paid $26.38M.
| Period end | Lessee, Operating Lease, Liability, to be Paid |
|---|---|
| 2024-12-31 | $10.12M 10-K · filed 2025-03-06 |
| 2023-12-31 | $15.69M 10-K · filed 2024-03-11 |
| 2022-12-31 | $21.11M 10-K · filed 2023-03-27 |
| 2021-12-31 | $26.38M 10-K/A · filed 2023-03-27 |
| 2021-09-30 | $27.69M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $28.96M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $30.24M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $31.51M 10-K · filed 2021-02-24 |
| 2020-09-30 | $32.78M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $34.02M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $35.26M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $36.50M 10-K · filed 2020-02-27 |
| 2019-09-30 | $37.74M 10-Q · filed 2019-11-07 |
| 2019-06-30 | $38.95M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $40.15M 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |